Wolfe Research has downgraded Starbucks to a neutral rating, citing an increasingly competitive coffee market.

Wolfe Research has identified several stocks with consistent dividend payments and solid track records, suggesting they could become dividend aristocrats amidst market volatility.

Off-price retailers, such as Dollar General, are anticipated to be most severely affected by a projected surge in gasoline prices, according to Wolfe Research, which could impact consumer spending habits.

Several financial firms have issued new ratings, price targets, or coverage initiations for biotech and pharmaceutical companies including Beam Therapeutics, Krystal Biotech, 4D Molecular Therapeutics, BioMarin Pharmaceutical, Vertex Pharmaceuticals, CRISPR Therapeutics AG, Regeneron Pharmaceuticals, and UniQure.

Wolfe Research has reiterated its 'Outperform' rating for RTX Corp following the company's deal with the Pentagon for a missile manufacturing framework.

Wolfe Research has noted conviction-driven opportunities within ACADIA Pharmaceuticals Inc.’s (ACAD) therapeutic domains, suggesting potential for growth.

Wolfe Research has adopted a bearish stance on Circle Internet Group (CRCL), citing lower EBITDA expectations.